Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS

Reuters

2025/10/21

Atossa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Advances RECAST Trial Testing <a href="https://laohu8.com/S/Z">$(Z)$</a>-Endoxifen for DCIS

Atossa Therapeutics Inc. has announced progress in the RECAST™ platform trial, which is focused on ductal carcinoma in situ (DCIS), a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST™, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02056) on October 21, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577827161"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577827161\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577827161?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577827161","market":"nz","top_or_hot":-1,"title":"Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances RECAST Trial Testing <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-Endoxifen for DCIS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atossa Therapeutics Inc. has announced progress in the RECAST™ platform trial, which is focused on ductal carcinoma in situ (DCIS), a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST™, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02056) on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-21 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances RECAST Trial Testing <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-Endoxifen for DCIS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atossa Therapeutics Inc. has announced progress in the RECAST™ platform trial, which is focused on ductal carcinoma in situ (DCIS), a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST™, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02056) on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL4wWWy4:1","article_id":"2577827161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577827161","pubTimestamp":1761048057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atossa Therapeutics Inc. has announced progress in the RECAST platform trial, which is focused on ductal carcinoma in situ , a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of -Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATOS":"Atossa Genetics Inc"},"translate_title":"Atossa Therapeutics推进RECAST试验测试(Z)-Endoxifen治疗DCIS","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9},"content_text":"Atossa Therapeutics Advances RECAST Trial Testing $(Z)$-Endoxifen for DCIS\n    \n\n        Atossa Therapeutics Inc. has announced progress in the RECAST™ platform trial, which is focused on ductal carcinoma in situ (DCIS), a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST™, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02056) on October 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}